Antibacterial, antioxidant or anti-inflammatory compositions comprising compounds isolated from agarwood

Agarwood-derived compounds provide a novel solution for Helicobacter pylori infections by combining antibacterial, antioxidant, and anti-inflammatory activities, addressing the limitations of standard therapies and enhancing treatment efficacy.

KR103043812B1Active Publication Date: 2026-11-06RES & BUSINESS FOUND SUNGKYUNKWAN UNIV +1
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
KR1020240025990
Authority / Receiving Office
KR · KR
Patent Type
Patents
Current Assignee / Owner
Filing Date
2024-02-22
Publication Date
2026-11-06
Estimated Expiration
2044-02-22

AI Technical Summary

Technical Problem

The standard triple therapy for Helicobacter pylori eradication, using proton pump inhibitors and antibiotics, faces issues such as reduced eradication rates due to resistance and side effects like altered taste and nausea, necessitating the development of more effective antibiotics.

Method used

Isolation of antibacterial, antioxidant, and anti-inflammatory compounds from agarwood, specifically Formulas 1 and 2 or their pharmaceutically acceptable salts, which are used in compositions for treating bacterial infections, reducing ROS and NO generation, and providing anti-inflammatory effects.

Benefits of technology

The agarwood-derived compounds exhibit significant antibacterial activity against Helicobacter pylori, high antioxidant capacity, and potent anti-inflammatory properties, offering a potential alternative to traditional antibiotics with improved efficacy and reduced side effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 112024020841588-PAT00027_ABST
    Figure 112024020841588-PAT00027_ABST
Patent Text Reader

Abstract

The present invention relates to a compound isolated from the agarwood tree (Aquilaria agallocha) and an antibacterial, antioxidant, and anti-inflammatory composition comprising said compound, wherein said compound has antibacterial activity against Helicobacter pylori and has antioxidant and anti-inflammatory activity, and can be usefully used in the field of medicine.
Need to check novelty before this filing date? Find Prior Art

Description

Technology Field

[0001] The present invention relates to a compound isolated from agarwood and a composition for antibacterial, antioxidant, and anti-inflammatory purposes comprising said compound. Background Technology

[0003] Currently, the standard triple therapy (proton pump inhibitor, PPI + two antibiotics) is used for the eradication of Helicobacter pylori, the cause of gastric cancer. Generally, omeprazole is used as the PPI, and treatment is typically administered using a combination of amoxicillin, clarithromycin, or metronidazole as the two antibiotics. However, the use of these antibiotics presents problems, such as reduced eradication rates due to increased resistance, altered taste, and nausea. Therefore, there is a need to develop new antibiotics that are more effective while addressing the shortcomings of existing antibiotics.

[0004] Accordingly, the inventors discovered that natural compounds isolated from agarwood possess antibacterial, antioxidant, and anti-inflammatory activities, and completed the present invention. Prior art literature

[0006] U.S. Patent Publication No. 2011 / 0160152 A1 The problem to be solved

[0007] The object of the present invention is to provide a novel compound of Formula 1 or Formula 2 or a pharmaceutically acceptable salt thereof.

[0008] Another object of the present invention is to provide an antimicrobial composition comprising, as an active ingredient, one or more compounds selected from the group consisting of Formulas 3 to 5 or pharmaceutically acceptable salts thereof.

[0009] Another objective of the present invention is to provide a pharmaceutical composition for the prevention or treatment of bacterial infectious diseases comprising, as an active ingredient, one or more compounds selected from the group consisting of Formulas 3 to 5 or pharmaceutically acceptable salts thereof.

[0010] Another object of the present invention is to provide an antioxidant composition comprising one or more compounds selected from the group consisting of Formulas 2 to 5 or pharmaceutically acceptable salts thereof as an active ingredient.

[0011] Another object of the present invention is to provide an anti-inflammatory composition comprising one or more compounds selected from the group consisting of Formulas 2 to 5 or pharmaceutically acceptable salts thereof as an active ingredient. means of solving the problem

[0013] To achieve the above objective, the present invention provides a novel compound of Formula 1 or Formula 2 or a pharmaceutically acceptable salt thereof.

[0014] [Chemical Formula 1]

[0015]

[0016] [Chemical Formula 2]

[0017]

[0018] In one embodiment of the present invention, the compound is agarwood ( Aquilaria agallocha It may be separated from ).

[0019] In addition, the present invention provides an antimicrobial composition comprising one or more compounds selected from the group consisting of the following chemical formulas 3 to 5, or a pharmaceutically acceptable salt thereof, as an active ingredient.

[0020] [Chemical Formula 3]

[0021]

[0022] [Chemical Formula 4]

[0023]

[0024] [Chemical Formula 5]

[0025]

[0026] As mentioned above,

[0027] R 1 and R 2 Each is independently H, OH, or OCH3;

[0028] R 3 and R 4 Each is independently H or OH;

[0029] R 5 and R 6 Each is independently H or OCH3.

[0030] In one embodiment of the present invention, the compound is agarwood ( Aquilaria agallocha It may be separated from ).

[0031] In one embodiment of the present invention, the compound is agarwood ( Aquilaria agallocha It may be isolated from the ethyl acetate fraction of the methanol extract.

[0032] In one embodiment of the present invention, in the above formula 3, R 1 is H, OH, or OCH3, and R 2 is H; or R 1 is H or OCH3, and R 2 It may be OH or OCH3.

[0033] In one embodiment of the present invention, in the above formula 4, R 3 and R 4 is H or OH, and R 5 and R 6 It may be H or OCH3.

[0034] In one embodiment of the present invention, the compound is N-trans -feruloyltyramine, (2 E )-3-(4-hydroxy-3-methoxyphenyl)-N -[(2 S It may be selected from the group consisting of )-2-(4-hydroxyphenyl)-2-methoxyethyl]-2-propenamide, 4,4'-(1,7-heptanediyl)bis[phenol], meso-octahydrocurcumin, and diosniponol A, and more preferably, the compound may be 4,4'-(1,7-heptanediyl)bis[phenol].

[0035] In one embodiment of the present invention, the composition may have antibacterial activity against Helicobacter pylori.

[0036] In addition, the present invention provides a pharmaceutical composition for the prevention or treatment of bacterial infectious diseases comprising one or more compounds selected from the group consisting of Formulas 3 to 5 or a pharmaceutically acceptable salt thereof as an active ingredient.

[0037] In one embodiment of the present invention, the bacterial infection may be Helicobacter pylori infection.

[0038] In addition, the present invention provides an antioxidant composition comprising one or more compounds selected from the group consisting of Formulas 2 to 5 or a pharmaceutically acceptable salt thereof as an active ingredient.

[0039] In one embodiment of the present invention, the compound is ( Z )-3-(4-hydroxy-3-methoxybenzyl-idene)-4 R -(4-hydroxyphenyl)pyrrolidin-2-one), N-trans - Feruloyltyramine, N-trans - Caffeol tyramine, (3 R, 5 R It may be selected from the group consisting of )-1,7-bis(4-hydroxy-3-methoxyphenyl)-3,5-heptanediol, meso-octahydrocurcumin and diosniponol A.

[0040] In one embodiment of the present invention, the compound may have activity that inhibits the generation of reactive oxygen species (ROS) or activity that scavenges DPPH radicals.

[0041] In addition, the present invention provides an anti-inflammatory composition comprising one or more compounds selected from the group consisting of Formulas 2 to 5 or a pharmaceutically acceptable salt thereof as an active ingredient.

[0042] In one embodiment of the present invention, the compound is Z )-3-(4-hydroxy-3-methoxybenzyl-idene)- 4R -(4-hydroxyphenyl)pyrrolidin-2-one), N-trans -ferulloyltyramine, 4,4'-(1,7-heptanediyl)bis[phenol], (3 R, 5 R It may be selected from the group consisting of )-1,7-bis(4-hydroxy-3-methoxyphenyl)-3,5-heptanediol and diosniponol A.

[0043] In one embodiment of the present invention, the compound may have an activity that inhibits the generation of reactive oxygen species (ROS) or an activity that inhibits the generation of nitric oxide (NO). Effects of the invention

[0045] Agarwood of the present invention ( Aquilaria agallocha The compound isolated from ) has antibacterial activity against Helicobacter pylori and has antioxidant and anti-inflammatory properties, so it can be usefully used in the medical field. Brief explanation of the drawing

[0047] Fig. 1 is an agarwood tree ( Aquilaria agallocha This shows 12 compounds isolated from the extract. Specific details for implementing the invention

[0048] The present invention will be described in detail below.

[0049] The terms used in this invention have been selected based on currently widely used general terms whenever possible, taking into account the functions of the invention; however, these terms may vary depending on the intent of those skilled in the art or the emergence of new technologies. Additionally, in specific cases, terms may be arbitrarily selected, and in such cases, their meanings will be described in detail in the description section of the relevant embodiments. Therefore, the terms used in this invention should be defined not merely by their names, but based on their meanings and the overall content of the invention.

[0050] In the present invention, when a component or step is described as "comprising," this means that, unless specifically stated otherwise, it does not exclude other components or steps but may include additional components or steps.

[0052] The present invention provides a novel compound of Formula 1 or Formula 2 or a pharmaceutically acceptable salt thereof.

[0053] [Chemical Formula 1]

[0054]

[0055] [Chemical Formula 2]

[0056]

[0057] In the present invention, the compound of Formula 1 is ( 1R, 2R )-cannabicin B, and the compound of chemical formula 2 is ( Z )-3-(4-hydroxy-3-methoxybenzyl-idene)-4 R It may be (4-hydroxyphenyl)pyrrolidin-2-one).

[0058] In the present invention, the compound is agarwood ( Aquilaria agallochaThe compound may be separated from ). The compound may be separated from an extract obtained from water, an organic solvent, or a mixture thereof, and may be separated by known methods commonly used in the art, such as chromatography.

[0059] The above organic solvent may be selected from the group consisting of methanol, ethanol, propanol, isopropanol, butanol, acetone, ether, benzene, chloroform, ethyl acetate, methylene chloride, hexane, and cyclohexane, but is not limited thereto.

[0060] The above agarwood is a natural product mainly distributed in Asian regions such as China, India, Indonesia, Malaysia, and Thailand, and in the present invention, among the agarwood, Aquilaria agallocha ( Aquilaria agallocha It concerns compounds isolated from ) species.

[0061] In addition, the present invention provides an antimicrobial composition comprising one or more compounds selected from the group consisting of the following chemical formulas 3 to 5, or a pharmaceutically acceptable salt thereof, as an active ingredient.

[0062] [Chemical Formula 3]

[0063]

[0064] [Chemical Formula 4]

[0065]

[0066] [Chemical Formula 5]

[0067]

[0068] As mentioned above,

[0069] R 1 and R 2 Each is independently H, OH, or OCH3;

[0070] R 3 and R 4 Each is independently H or OH;

[0071] R5 and R 6 Each is independently H or OCH3.

[0073] In the present invention, the compound is agarwood ( Aquilaria agallocha It may be separated from ), preferably agarwood ( Aquilaria agallocha ) It may be isolated from the ethyl acetate fraction of the methanol extract, and more preferably from agarwood ( Aquilaria agallocha It may be a compound separated from subfraction E2 or fraction E3 obtained by performing silica gel column chromatography on the ethyl acetate fraction of the methanol extract.

[0074] In the present invention, in the above chemical formula 3, R 1 is H, OH, or OCH3, and R 2 is H; or R 1 is H or OCH3, and R 2 It may be OH or OCH3.

[0075] In the present invention, a compound represented by Chemical Formula 3 3-8 R in Chemical Formula 3 1 and R 2 This is as shown in Table 1 below.

[0076] Compound R1 R2 3 OCH3 H 4 OCH3 OCH3 5 H OH 6 OCH3 OH 7 OH H 8 H H

[0078] In the present invention, in the above chemical formula 4, R 3 and R 4 is H or OH, and R 5 and R 6 It may be H or OCH3.

[0079] In the present invention, a compound represented by Chemical Formula 4 9-11 R in Chemical Formula 4 3 to R 6 It is as shown in Table 2 below.

[0080] Compound R3 R4 R5 R6 9 H H H H 10 OCH3 OCH3 OH OH 11 OCH3 OCH3 OH OH

[0082] In the present invention, one or more compounds selected from the group consisting of Formulas 3 to 5 are N-trans -feruloyltyramine, (2 E )-3-(4-hydroxy-3-methoxyphenyl)- N -[(2 S )-2-(4-hydroxyphenyl)-2-methoxyethyl]-2-propenamide, (-)- N -( p -Coomaroil) Octopamine, (2 E )- N -[(2 R )-2-hydroxy-2-(4-hydroxyphenyl)ethyl]-3-(4-hydroxy-3-methoxyphenyl)-2-propenamide, N-trans - Caffeol tyramine, N-trans -Coumaroyltyramine, 4,4'-(1,7-heptanediyl)bis[phenol], (3 R, 5 R It may be selected from the group consisting of )-1,7-bis(4-hydroxy-3-methoxyphenyl)-3,5-heptanediol, meso-octahydrocurcumin and diosniponol A.

[0083] Preferably, one or more compounds selected from the group consisting of Formulas 3 to 5 are N-trans -feruloyltyramine, (2 E )-3-(4-hydroxy-3-methoxyphenyl)- N -[(2 S It may be selected from the group consisting of )-2-(4-hydroxyphenyl)-2-methoxyethyl]-2-propenamide, 4,4'-(1,7-heptanediyl)bis[phenol], meso-octahydrocurcumin, and diosniponol A, and more preferably 4,4'-(1,7-heptanediyl)bis[phenol].

[0084] In the present invention, the composition may have antibacterial activity against Helicobacter pylori.

[0085] In addition, the present invention may provide a pharmaceutical composition for the prevention or treatment of bacterial infectious diseases comprising one or more compounds selected from the group consisting of formulas 3 to 5 or pharmaceutically acceptable salts thereof as active ingredients.

[0086] In the present invention, the bacterial infectious disease may be Helicobacter pylori infection, but is not limited thereto.

[0087] The above Helicobacter pylori infection is a disease caused by infection with Helicobacter pylori bacteria and can be selected from a group consisting of gastritis, gastric ulcer, duodenal ulcer, gastric hyperplastic polyp, gastric cancer, gastric lymphoma, digestive cancer, pancreatitis, inflammatory bowel disease and functional digestive disorders (upper abdominal fullness, upper abdominal pain, belching, abdominal distension, initial fullness, nausea, vomiting, reflux, heartburn, loss of appetite, etc.).

[0088] The composition according to the present invention can be used as an antimicrobial agent or bactericidal agent for the prevention or treatment of Helicobacter pylori infection, and can be used in combination with previously known antimicrobial agents or bactericidal agents.

[0089] In addition, the present invention provides an antioxidant composition comprising one or more compounds selected from the group consisting of Formulas 2 to 5 or a pharmaceutically acceptable salt thereof as an active ingredient.

[0090] In the present invention, one or more compounds selected from the group consisting of Formulas 2 to 5 are ( Z )-3-(4-hydroxy-3-methoxybenzyl-idene)-4 R -(4-hydroxyphenyl)pyrrolidin-2-one), N-trans -feruloyltyramine, (2 E )-3-(4-hydroxy-3-methoxyphenyl)- N -[(2 S )-2-(4-hydroxyphenyl)-2-methoxyethyl]-2-propenamide, (-)- N -(p -Coomaroil) Octopamine, (2 E )- N -[(2 R )-2-hydroxy-2-(4-hydroxyphenyl)ethyl]-3-(4-hydroxy-3-methoxyphenyl)-2-propenamide, N-trans - Caffeol tyramine, N-trans -Coumaroyltyramine, 4,4'-(1,7-heptanediyl)bis[phenol], (3 R, 5 R It may be selected from the group consisting of )-1,7-bis(4-hydroxy-3-methoxyphenyl)-3,5-heptanediol, meso-octahydrocurcumin and diosniponol A.

[0091] Preferably, ( Z )-3-(4-hydroxy-3-methoxybenzyl-idene)-4 R -(4-hydroxyphenyl)pyrrolidin-2-one), N-trans - Feruloyltyramine, N-trans - Caffeol tyramine, (3 R, 5 R It may be selected from the group consisting of )-1,7-bis(4-hydroxy-3-methoxyphenyl)-3,5-heptanediol, meso-octahydrocurcumin and diosniponol A.

[0092] In the present invention, the compound may have activity that inhibits the generation of ROS (reactive oxygen species) or activity that scavenges DPPH radicals.

[0093] In addition, the present invention provides an anti-inflammatory composition comprising one or more compounds selected from the group consisting of Formulas 2 to 5 or a pharmaceutically acceptable salt thereof as an active ingredient.

[0094] In the present invention, one or more compounds selected from the group consisting of Formulas 2 to 5 are ( Z )-3-(4-hydroxy-3-methoxybenzyl-idene)-4 R -(4-hydroxyphenyl)pyrrolidin-2-one), N-trans-feruloyltyramine, (2 E )-3-(4-hydroxy-3-methoxyphenyl)- N -[(2 S )-2-(4-hydroxyphenyl)-2-methoxyethyl]-2-propenamide, (-)- N -( p -Coomaroil) Octopamine, (2 E )- N -[(2 R )-2-hydroxy-2-(4-hydroxyphenyl)ethyl]-3-(4-hydroxy-3-methoxyphenyl)-2-propenamide, N-trans - Caffeol tyramine, N-trans -Coumaroyltyramine, 4,4'-(1,7-heptanediyl)bis[phenol], (3 R, 5 R It may be selected from the group consisting of )-1,7-bis(4-hydroxy-3-methoxyphenyl)-3,5-heptanediol, meso-octahydrocurcumin and diosniponol A.

[0095] Preferably, Z )-3-(4-hydroxy-3-methoxybenzyl-idene)-4 R -(4-hydroxyphenyl)pyrrolidin-2-one), N-trans -ferulloyltyramine, 4,4'-(1,7-heptanediyl)bis[phenol], (3 R, 5 R It may be selected from the group consisting of )-1,7-bis(4-hydroxy-3-methoxyphenyl)-3,5-heptanediol and diosniponol A.

[0096] In the present invention, the compound may have an activity that inhibits the generation of ROS (reactive oxygen species) or an activity that inhibits the generation of NO (nitric oxide).

[0097] The composition of the present invention may be a pharmaceutical composition or a food composition.

[0098] The above pharmaceutical composition may further comprise a pharmaceutically acceptable carrier. In the present invention, the term "pharmaceutically acceptable" means exhibiting properties that are non-toxic to cells or humans exposed to the composition. The carrier may be used without limitation as long as it is known in the art, such as buffers, preservatives, analgesics, solubilizers, isotonic agents, stabilizers, bases, excipients, lubricants, etc.

[0099] In addition, the pharmaceutical composition of the present invention may be formulated and used in the form of oral formulations such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, and aerosols, as well as external preparations, suppositories, and sterile injectable solutions, according to conventional methods. Furthermore, it may be used in the form of external skin preparations such as ointments, lotions, sprays, patches, creams, powders, suspensions, gels, or gels. Carriers, excipients, and diluents that may be included in the composition of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil. When formulating, the composition is prepared using diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants.

[0100] Solid dosage forms for oral administration include tablets, pills, powders, granules, capsules, etc., and these solid dosage forms are prepared by mixing at least one excipient, such as starch, calcium carbonate, sucrose or lactose, gelatin, etc., with the above-mentioned Psychotria rubra extract. In addition to simple excipients, lubricants such as magnesium styrate and talc are also used. Liquid dosage forms for oral administration include suspensions, oral liquids, emulsions, syrups, etc., and may contain various excipients, such as humectants, sweeteners, flavorings, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin. Preparations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, and suppositories. As non-aqueous solvents and suspending agents, propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate may be used. As bases for suppositories, Witepsol, Macrogol, Tween 61, cocoa paste, laurin paste, glycerogelatin, etc. may be used.

[0101] The pharmaceutical composition of the present invention is administered in a pharmaceutically effective amount. The term "administration" in the present invention means introducing a specific substance into an individual by an appropriate method, and the route of administration of said composition may be any general route as long as it can reach the target tissue. It may be administered intraperitoneally, intravenously, intramuscularly, subcutaneously, intradermally, orally, topically, intranasally, intrapulmonaryly, or rectally, but is not limited thereto.

[0102] The term "individual" above refers to all animals, including humans, rats, mice, livestock, etc. Preferably, it may be mammals, including humans.

[0103] The term "pharmaceuticalally effective dose" above refers to an amount sufficient to treat a disease with a reasonable benefit / risk ratio applicable to medical treatment and that does not cause adverse effects. The effective dose level can be readily determined by a person skilled in the art based on factors including the patient's gender, age, weight, health status, type and severity of the disease, drug activity, sensitivity to the drug, method of administration, time of administration, route of administration, and elimination rate, duration of treatment, drugs used in combination or simultaneously, and other factors well known in the medical field. The above recommended dose may be administered once a day or divided into several doses.

[0104] The above food composition may include all foods in the conventional sense and may be used interchangeably with terms known in the art, such as functional foods and health functional foods.

[0105] The term "functional food" in the present invention refers to a food manufactured and processed using raw materials or ingredients having functional properties useful to the human body as defined in Act No. 6727 of the Health Functional Foods Act, and "functionality" means consuming for the purpose of obtaining useful effects for health purposes, such as regulating nutrients or physiological actions on the structure and function of the human body.

[0106] The term "health functional food" in the present invention refers to a food manufactured or processed by methods such as extraction, concentration, purification, or mixing, using a specific component as a raw material or a specific component contained in a food raw material for the purpose of health supplementation, and is a food designed and processed to sufficiently exert biological regulatory functions on the body, such as biological defense, regulation of biological rhythms, and prevention and recovery of disease, through said component, and the composition for the health food can perform functions related to the prevention of disease and recovery of disease.

[0107] There are no restrictions on the types of food in which the composition of the present invention can be used. In addition, the composition of the present invention may be prepared by mixing other suitable auxiliary ingredients that may be included in food and known additives, depending on the choice of a person skilled in the art. Examples of foods to which it can be added include meat, sausage, bread, chocolate, candies, snacks, confectionery, pizza, ramen, other noodles, chewing gum, dairy products including ice cream, various soups, beverages, tea, drinks, alcoholic beverages, and vitamin complexes, and it may be prepared by adding it to juices, teas, jellies, and juices prepared using the extract and fractions thereof according to the present invention as main ingredients.

[0108] In addition, the foods to which the present invention can be applied may include all foods, such as special nutritional foods (e.g., infant formula, baby food, etc.), processed meat products, fish products, tofu products, jelly products, noodles (e.g., ramen, noodles, etc.), health supplements, seasoning foods (e.g., soy sauce, soybean paste, red pepper paste, mixed sauce, etc.), sauces, confectionery products (e.g., snacks), dairy products (e.g., fermented milk, cheese, etc.), other processed foods, kimchi, pickled foods (various types of kimchi, pickled vegetables, etc.), beverages (e.g., fruit and vegetable beverages, soy milk, fermented beverages, etc.), and natural seasonings (e.g., ramen soup, etc.).

[0109] When the health functional food composition of the present invention is used in the form of a beverage, it may contain various sweeteners, flavorings, or natural carbohydrates as additional ingredients, as in conventional beverages. In addition to the above, the health functional food composition of the present invention may contain various nutritional supplements, vitamins, electrolytes, flavorings, colorings, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonating agents used in carbonated beverages, etc. Furthermore, it may contain fruit pulp for the production of natural fruit juices, fruit juice beverages, and vegetable beverages.

[0111] The present invention will be explained in more detail below through examples. These examples are intended to explain the invention more specifically, and the scope of the invention is not limited to these examples.

[0113] Example 1. Agarwood ( Aquilaria agallocha Separation of compounds from )

[0114] Powdered agarwood in 700 mL of 80% methanol ( Aquilaria agallocha 70 g was added and extracted at room temperature for 12 to 14 hours. This process was repeated three times, filtered, and concentrated to obtain 24.7 g of crude extract of Agarwood. Subsequently, the obtained crude extract was dissolved in 700 mL of triple-distilled water, followed by solvent fractionation with 700 mL of ethyl acetate and concentration, resulting in 12.5 g of ethyl acetate fraction. Subsequently, silica gel column chromatography (dichloromethane:methanol = 50:1 → 30:1 → 10:1 → 1:1; and 100% methanol) was performed, yielding fractions E1 (504 mg), E2 (750 mg), E3 (10 g), and E4 (40 mg).

[0115] Subsequently, to obtain subfractions of the E2 fraction, preparative high-performance liquid chromatography (prep-HPLC) was performed using methanol and triple-distilled water to obtain six subfractions E21 to E26. In the above, subfraction E21 (119 mg) was subjected to semi-preparative high-performance liquid chromatography (semi-prep-HPLC) using methanol and triple-distilled water, and as a result, the compound 3 (6.9 mg), 4 (1.5 mg), 10 (16.9 mg), 11 (2.5 mg) and 12(2.3 mg) was isolated (Fig. 1).

[0116] In addition, subfraction E25 (147 mg) was obtained by performing Sephadex LH-20 (80% methanol, 100% methanol) using methanol and triple-distilled water. The obtained subfraction was subjected to semi-preparative high-performance liquid chromatography (semi-prep-HPLC) using methanol and triple-distilled water to determine the compound 9 (4.2 mg) was isolated (Fig. 1).

[0117] Fraction E3 was also subjected to preparative high-performance liquid chromatography (prep-HPLC) using methanol and triple-distilled water to obtain subfractions of Fraction E3. The obtained subfractions were subjected to semi-preparative high-performance liquid chromatography (semi-prep-HPLC) using methanol and triple-distilled water, and as a result, the compound 1 (1.2 mg), 2 (2.5 mg), 5 (0.8 mg) , 6 (2.0 mg) , 7 (4.0 mg) and 8 (1.1 mg) was isolated (Fig. 1).

[0118] The above separated substance is (1 R, 2 R )-Cannabisin B ( 1 ), ( Z )-3-(4-hydroxy-3-methoxybenzyl-idene)-4 R -(4-hydroxyphenyl)pyrrolidin-2-one) ( 2 ), N-trans - Feruloyltyramine ( 3 ), (2 E)-3-(4-hydroxy-3-methoxyphenyl)- N -[(2 S )-2-(4-hydroxyphenyl)-2-methoxyethyl]-2-propenamide ( 4 ), (-)- N -( p -Coomaroil) Octopamine ( 5 ), (2 E )- N -[(2 R )-2-hydroxy-2-(4-hydroxyphenyl)ethyl]-3-(4-hydroxy-3-methoxyphenyl)-2-propenamide ( 6 ), N-trans - Caffeoyl tyramine ( 7 ), N-trans -Cumaroyltyramine ( 8 ), 4,4'-(1,7-heptanediyl)bis[phenol] ( 9 ), (3 R, 5 R )-1,7-bis(4-hydroxy-3-methoxyphenyl)-3,5-heptanediol ( 10 ), meso-octahydrocurcumin ( 11 ) and diosniponol A ( 12 It is. Among these, compounds 1 and 2 It was identified as a novel compound being isolated and reported for the first time from natural products.

[0120] Example 2. Evaluation of the antimicrobial activity of compounds isolated from agarwood extract

[0121] Phenolic amide compounds isolated from agarwood extract (compounds 1-8 ) and diarylheptanoid compounds (compounds 9-12 Regarding ), Helicobacter pylori, one of the human pathogenic bacteria ( Helicobacter pyloriExperiments were conducted to evaluate the antimicrobial activity against Strain 51). MIC values ​​were measured using the standard broth serial dilution method according to CLSI (Clinical and Laboratory Standard Institute) guidelines. Quercetin and Metronidazole, a representative antibiotic, were used as positive controls. Statistical analysis of the results was performed using the ANOVA (Analysis of Variance) procedure of the SPSS (Statistical Package for the Social Sciences, SPSS Inc. USA) package program, and statistical significance was determined using Duncan's multiple range test. p Tested < 0.05.

[0122] As a result, as shown in Table 3 and Figure 2 below, the compound 3, 4, 9, 11 and 12 It was confirmed that it exhibited significant inhibitory activity against Helicobacter pylori, with inhibition rates (%) of 30.4%, 32.2%, 94.8%, 28.6%, and 27.8%, respectively. In particular, the compound 9 The inhibition rate of Helicobacter pylori was 94.8%, showing significantly higher inhibitory activity compared to the positive control quercetin, and similar inhibitory activity to metronidazole, a representative antibiotic.

[0124] Compound (100 μM) Inhibition (%) 1 12.0 ± 0.7 e 2 14.4 ± 0.1 e 3 30.4 ± 4.3 c 4 32.2 ± 0.4 c 5 6.8 ± 3.7 f 6 15.5 ± 1.9 e 7 10.8 ± 0.7 ef 8 13.9 ± 2.4 e 9 94.8 ± 0.7 a 10 21.0 ± 1.5 d 11 28.6 ± 2.5 c 12 27.8 ± 0.1 c Quercetin 38.4 ± 2.3 b Metronidazole 96.6 ± 0.5 a

[0125] All values ​​are mean ± standard deviation; and

[0126] Different initials in the same column are recognized as statistically significant ( p < 0.05).

[0128] Subsequently, a compound that exhibited high inhibitory activity against Helicobacter pylori 3, 4, 9, 11 and 12 The MIC values ​​were measured for. As a result, as shown in Table 4 below, the compound 3, 4, 9, 11 and 12 The MIC values ​​were confirmed to be 25 μg / mL, 12.5 μg / mL, 6.3 μg / mL, 25 μg / mL, and 12.5 μg / mL, respectively. In particular, the compound 9 It showed a very low MIC value, and additionally, MIC 50 and MIC 90 As a result of the examination, it was confirmed that they exhibited significantly high inhibitory activity against Helicobacter pylori, with values ​​of 50 μg / mL and 98 μg / mL, respectively.

[0130] Compound MIC MIC 50 MIC 90 3 25 > 100 - 4 12.5 > 100 - 9 6.3 50 98 11 25 > 100 - 12 12.5 > 100 -

[0132] Example 3. Evaluation of the antioxidant and anti-inflammatory activities of compounds isolated from agarwood extract

[0133] Phenolic amide compounds isolated from agarwood extract (compounds 1-8 ) and diarylheptanoid compounds (compounds 9-12Experiments were conducted to evaluate the antioxidant and anti-inflammatory activities of ). In the antioxidant experiment, Trolox was used as a positive control, and the antioxidant value was expressed as mmol TE (Trolox Equivalent) / mol. In the anti-inflammatory experiment, after treating RAW 264.7 cell lines with a 100 μM concentration of the compound that did not exhibit cytotoxicity, the inhibitory activity (%) of ROS (reactive oxygen species) and NO (nitric oxide) production relative to the negative control (LPS) was measured. Statistical analysis was performed using the ANOVA (Analysis of Variance) procedure of the SPSS (Statistical Package for the Social Sciences, SPSS Inc. USA) package program, and statistical significance was determined using Duncan's multiple range test. p Tested < 0.05.

[0134] As a result, as shown in Table 5 below, the compound 2, 3 , 10 and 12 The ROS generation inhibitory activities were confirmed to be 68.2%, 32.5%, 28.5%, and 26.9%, respectively, and the compound 2 and 9 The NO production inhibitory activities of were confirmed to be 74.9% and 42.4%, respectively, and the compound 2 , 3, 7, 10, 11 and 12 The DPPH radical scavenging activity (mmol TE / mol) of was confirmed to be 196, 200, 214, 410, 338, and 204 mmol TE / mol, respectively. Thus, the compound 2, 3, 9, 10 and 12 It was confirmed that it possesses significant anti-inflammatory activity. In addition, the compound 2, 3, 7, 10, 11 and 12 It was confirmed that it possesses significant antioxidant activity. In particular, the compound 2It was confirmed that it possesses the highest anti-inflammatory activity by showing the highest inhibitory activity on ROS and NO production. In addition, the compound 10 It was confirmed that it has the highest antioxidant activity as it was found to have the highest DPPH radical scavenging ability value.

[0136] Compound ROS generation inhibitory activity (%) NO production inhibitory activity (%) DPPH radical scavenging activity (mmol TE / mol) 1 9.8 ± 5.2 d ND 67 ± 22 e 2 68.2 ± 4.0 a 74.9 ± 1.9 a 196 ± 30 c 3 32.5 ± 3.7 b 9.4 ± 3.2 c 200 ± 37 c 4 16.7 ± 5.9 cd 0.6 ± 0.3 e 154 ± 39 d 5 13.4 ± 8.5 cd 8.2 ± 3.3 c 55 ± 26 e 6 14.0 ± 9.3 cd 2.9 ± 0.2 de 139 ± 24 d 7 19.6 ± 5.5 c 10.9 ± 2.9 c 214 ± 23 c 8 12.4 ± 4.3 cd 10.4 ± 3.3 c 50 ± 20 e 9 10.5 ± 9.0 d 42.4 ± 3.6 b 38 ± 20 e 10 28.5 ± 5.7 b 7.2 ± 1.9 cd 410 ± 45 a 11 12.3 ± 4.9 cd 6.0 ± 3.0 cd 338 ± 39 b 12 26.9 ± 3.6 b 7.5 ± 0.6 cd 204 ± 31 c

[0137] All values ​​are mean ± standard deviation; and

[0138] Different initials in the same column are recognized as statistically significant ( p < 0.05).

[0140] The foregoing description of the present invention is for illustrative purposes only, and those skilled in the art will understand that other specific forms can be easily modified without altering the technical spirit or essential features of the present invention. Therefore, the embodiments described above should be understood as illustrative in all respects and not restrictive. For example, each component described as a single unit may be implemented in a distributed manner, and components described as distributed may likewise be implemented in a combined form.

[0141] The scope of the present invention is defined by the claims set forth below, and all modifications or variations derived from the meaning and scope of the claims and equivalent concepts thereof should be interpreted as being included within the scope of the present invention.

Claims

Claim 1 A novel compound of Formula 1 or Formula 2 below, or a pharmaceutically acceptable salt thereof: [Formula 1] [Chemical Formula 2] . Claim 2 In claim 1, the compound is agarwood ( Aquilaria agallocha A compound or a pharmaceutically acceptable salt thereof that is separated from ). Claim 3 N-trans -feruloyltyramine, (2 E )-3-(4-hydroxy-3-methoxyphenyl)- N -[( 2S An antibacterial composition comprising, as an active ingredient, a compound selected from the group consisting of )-2-(4-hydroxyphenyl)-2-methoxyethyl]-2-propenamide, 4,4'-(1,7-heptanediyl)bis[phenol], meso-octahydrocurcumin, and diosniponol A. Claim 4 In claim 3, the compound is agarwood ( Aquilaria agallocha An antibacterial composition separated from ). Claim 5 In claim 4, the above compound is agarwood ( Aquilaria agallocha An antibacterial composition isolated from the ethyl acetate fraction of a methanol extract. Claim 6 delete Claim 7 delete Claim 8 delete Claim 9 An antibacterial composition according to claim 3, wherein the compound is 4,4'-(1,7-heptanediyl)bis[phenol]. Claim 10 An antibacterial composition according to claim 3, wherein the composition has antibacterial activity against Helicobacter pylori. Claim 11 N-trans -feruloyltyramine, (2 E )-3-(4-hydroxy-3-methoxyphenyl)- N -[( 2S A pharmaceutical composition for the prevention or treatment of a bacterial infectious disease comprising, as an active ingredient, a compound selected from the group consisting of )-2-(4-hydroxyphenyl)-2-methoxyethyl]-2-propenamide, 4,4'-(1,7-heptanediyl)bis[phenol], meso-octahydrocurcumin, and diosniponol A, wherein the bacterial infectious disease is Helicobacter pylori infection. Claim 12 delete Claim 13 ( Z )-3-(4-hydroxy-3-methoxybenzyl-idene)-4 R -(4-hydroxyphenyl)pyrrolidin-2-one), N-trans -Antioxidant composition comprising a compound selected from the group consisting of feruloyltyramine, meso-octahydrocurcumin, and diosniponol A as an active ingredient. Claim 14 delete Claim 15 An antioxidant composition according to claim 13, wherein the compound has activity of inhibiting the generation of ROS (reactive oxygen species) or activity of scavenging DPPH radicals. Claim 16 ( Z )-3-(4-hydroxy-3-methoxybenzyl-idene)-4 R -(4-hydroxyphenyl)pyrrolidin-2-one), N-trans -ferulloyltyramine, 4,4'-(1,7-heptanediyl)bis[phenol], (3 R, 5 R An anti-inflammatory composition comprising, as an active ingredient, a compound selected from the group consisting of )-1,7-bis(4-hydroxy-3-methoxyphenyl)-3,5-heptanediol and diosniponol A. Claim 17 delete Claim 18 An anti-inflammatory composition according to claim 16, wherein the compound has activity of inhibiting the generation of ROS (reactive oxygen species) or activity of inhibiting the generation of NO (nitric oxide).

Citation Information

Patent Citations

  • Novel Compositions for the Enhancement of the Anti-oxidant Potential of Hydrogenated Curcuminoids or Combinations Thereof

    US20090318565A1

  • Hemp sprout products and methods for producing same

    WO2021252947A1